Dimensional Fund Advisors LP Sells 6,437 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Dimensional Fund Advisors LP cut its stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 11.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 48,663 shares of the company’s stock after selling 6,437 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Xeris Biopharma were worth $109,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Simplicity Wealth LLC bought a new position in shares of Xeris Biopharma in the second quarter worth approximately $27,000. Allspring Global Investments Holdings LLC boosted its holdings in Xeris Biopharma by 4,512.5% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 16,282 shares of the company’s stock worth $37,000 after buying an additional 15,929 shares during the period. Bayesian Capital Management LP purchased a new stake in Xeris Biopharma in the 1st quarter worth $37,000. China Universal Asset Management Co. Ltd. raised its holdings in Xeris Biopharma by 66.0% during the first quarter. China Universal Asset Management Co. Ltd. now owns 26,516 shares of the company’s stock valued at $59,000 after acquiring an additional 10,543 shares during the period. Finally, Principal Financial Group Inc. lifted its position in shares of Xeris Biopharma by 100.4% in the first quarter. Principal Financial Group Inc. now owns 89,618 shares of the company’s stock valued at $198,000 after acquiring an additional 44,893 shares in the last quarter. 42.75% of the stock is currently owned by institutional investors.

Xeris Biopharma Stock Performance

Shares of NASDAQ XERS opened at $3.02 on Wednesday. The firm’s fifty day moving average is $2.76 and its two-hundred day moving average is $2.34. Xeris Biopharma Holdings, Inc. has a 52-week low of $1.46 and a 52-week high of $3.26. The company has a market cap of $447.73 million, a P/E ratio of -6.43 and a beta of 2.76.

Xeris Biopharma (NASDAQ:XERS) last issued its earnings results on Thursday, August 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01. The firm had revenue of $48.07 million for the quarter, compared to analysts’ expectations of $46.80 million. Xeris Biopharma had a negative return on equity of 16,662.63% and a negative net margin of 32.83%. During the same period in the previous year, the firm posted ($0.14) earnings per share. As a group, analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.4 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Xeris Biopharma in a research report on Thursday, August 15th.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.